Review Article
American Journal of BioMedicine
Volume 11, Issue 4, 2023, Pages 186-198 
10.18081/2333-5106/2023.11/186
M Ram 1 
, G Mishra , Ashish B Arora, Ram Chandra, Pankaj M Desai 
Received 04 June 2023; revised 17 September 2023; accepted 19 October 2023; published 13 December 2023
Abstract
Multiple sclerosis (MS) is an acquired disabling neurological disease of young adults, affecting approximately 2.3 million people worldwide. Multiple sclerosis is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of the differential involvement of motor, sensory, visual, and autonomic systems. TNF-α is an important cytokine of the inflammatory response involved in the pathogenesis of multiple sclerosis. A systematic literature review and a meta-analysis were conducted to discuss the tumor necrosis factor-α (TNF-α) polymorphism and prognosis of MS. PubMed and Embase databases were searched to find articles published between January 2000 and December 2022. Forty eligible studies, comprising 4220 patients with MS and 5321 controls, were included in the meta-analysis. In most populations, the pooled ORs (95%CI) for TNF 2/1 versus 1/1 were 0.95 (0.82-0.99), the pooled ORs (95%CI) for TNF 2/1 versus 1/1 and TNF 2/2 versus 2/1 were not statistically significant in the overall population. In conclusion, the data from this meta-analysis study show no significant role of TNF-α polymorphism in multiple sclerosis.
Keywords: Multiple sclerosis; TNF-α polymorphism; Systematic review
Copyright © 2023 Desai et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cited by CrossRef (5)
Cited by Scopus (2)
| 1. Kingwell E. Marriott JJ. Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13:128. https://doi.org/10.1186/1471-2377-13-128 |
||||
| 2. Compston A. Coles A. Multiple sclerosis. Lancet. 2008;372:1502-17. https://doi.org/10.1016/S0140-6736(08)61620-7 |
||||
| 3. Stevenson EV. Alexander JS. Yun JW. Becker F. Gonzalez-Toledo E. Chapter 16 - Mechanisms of blood-brain barrier disintegration in the pathophysiology of multiple sclerosis. In: Minagar A, editor. Multiple sclerosis. London: Academic Press; 2016. pp. 393-413. https://doi.org/10.1016/B978-0-12-800763-1.00016-6 |
||||
| 4. Perry M. Swain S. Kemmis-Betty S. Cooper P. Multiple sclerosis: summary of NICE guidance. BMJ. 2014;349:g5701. https://doi.org/10.1136/bmj.g5701 |
||||
| 5. Milo R. Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13:518-24. https://doi.org/10.1016/j.autrev.2014.01.012 |
||||
| 6. Scolding N. Barnes D. Cader S, et al. Association of British Neurologists: revised guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273-9. https://doi.org/10.1136/practneurol-2015-001139 |
||||
| 7. Lassmann H. van Horssen J. Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8:647-56. https://doi.org/10.1038/nrneurol.2012.168 |
||||
| 8. Mahad DH. Trapp PBD. Lassmann PH. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183-93. https://doi.org/10.1016/S1474-4422(14)70256-X |
||||
| 9. Cross AH. Wingerchuk DM. Weinshenker BG. Active and progressive: a new duality of MS classification. Neurology. 2014;83:206-7. https://doi.org/10.1212/WNL.0000000000000601 |
||||
| 10. Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83: 1022-1024. https://doi.org/10.1212/WNL.0000000000000768 |
||||
| 11. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 2014; 122: 231-266. https://doi.org/10.1016/B978-0-444-52001-2.00010-8 |
||||
| 12. Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 1999; 45 (05) 559-567. https://doi.org/10.1002/1531-8249(199905)45:5<559::AID-ANA3>3.0.CO;2-Q |
||||
| 13. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3 (04) 291-301. https://doi.org/10.1038/nrn784 |
||||
| 14. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21 (02) 81-92. https://doi.org/10.1023/A:1011064007686 |
||||
| 15. Swanton JK, Fernando KT, Dalton CM. , et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010; 16 (02) 156-165. https://doi.org/10.1177/1352458509353650 |
||||
| 16. Barkhof F, Filippi M, Miller DH. , et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-2069. https://doi.org/10.1093/brain/120.11.2059 |
||||
| 17. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4 (05) 281-288. https://doi.org/10.1016/S1474-4422(05)70071-5 |
||||
| 18. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23: 1123-1136. https://doi.org/10.1177/1352458517694432 |
||||
| 19. Chataway J. Schuerer N. Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213-21. https://doi.org/10.1016/S0140-6736(13)62242-4 |
||||
| 20. Montalban X. Hemmer B. Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. Neurology. 2016;86(Suppl 16):S49.001. https://doi.org/10.1212/WNL.86.16_supplement.S49.001 |
||||
| 21. Lublin F. Miller DH. Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075-84. https://doi.org/10.1016/S0140-6736(15)01314-8 |
||||
| 22. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545-558. https://doi.org/10.1038/nri3871 |
||||
| 23. Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005;106(2):163-177. https://doi.org/10.1016/j.pharmthera.2004.11.007 |
||||
| 24. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517. https://doi.org/10.1016/S0140-6736(08)61620-7 |
||||
| 25. Göbel K, Ruck T, Meuth SG. Cytokine signaling in multiple sclerosis: lost in translation. Mult Scler J. 2018;24(4):432-439. https://doi.org/10.1177/1352458518763094 |
||||
| 26. Kollias G, Douni E, Kassiotis G, et al. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999;58(suppl 1):I32-I39. https://doi.org/10.1136/ard.58.2008.i32 |
||||
| 27. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med. 1991;325(7):467-472. https://doi.org/10.1056/NEJM199108153250704 |
||||
| 28. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Nat Acad Sci. 1997;94(7):3195-3199. https://doi.org/10.1073/pnas.94.7.3195 |
||||
| 29. Ristić S, Lovrečić L, Starčević-Čizmarević N, et al. Tumor necrosis factor-α-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur Neurol. 2007;57(4):203-207. https://doi.org/10.1159/000099159 |
||||
| 30. El Fattah Nada MA, Labib DA. Tumor necrosis factor-alpha gene− 376 polymorphism and susceptibility to multiple sclerosis: an Egyptian study. J Neuroimmune Pharmacol. 2011;6(1):142-147. https://doi.org/10.1007/s11481-010-9220-0 |
||||
| 31. Tayel MY, Nazir A, Abdelhamid IM, et al. TNF-α −308 G>A and IL10-1082A>G polymorphisms as potential risk factors for lymphoproliferative disorders in autoimmune rheumatic diseases. Egypt J Med Hum Genet. 2020;21(1):1-13. https://doi.org/10.1186/s43042-019-0043-0 |
||||
File and statistics
Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.